Entrada Therapeutics, Inc. (TRDA)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
As of 12:37PM EDT. Market open.
| Previous close | 14.36 |
| Open | 14.41 |
| Bid | 14.17 x 100 |
| Ask | 14.57 x 100 |
| Day's range | 14.02 - 14.41 |
| 52-week range | 10.62 - 18.44 |
| Volume | |
| Avg. volume | 78,675 |
| Market cap | 480.738M |
| Beta (5Y monthly) | -0.39 |
| PE ratio (TTM) | 20.64 |
| EPS (TTM) | 0.69 |
| Earnings date | 10 May 2024 - 14 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 21.00 |
Simply Wall St.Entrada Therapeutics First Quarter 2024 Earnings: Beats Expectations
Entrada Therapeutics ( NASDAQ:TRDA ) First Quarter 2024 Results Key Financial Results Revenue: US$59.1m (up 134% from...
GlobeNewswireEntrada Therapeutics Reports First Quarter 2024 Financial Results
– Initiated dosing of the fourth and final cohort of Phase 1 clinical trial of ENTR-601-44 for the potential treatment of DMD with data readout on track for October of 2024 – – Achieved $75 million milestone payment from Vertex for the clinical advancement of its Phase 1/2 clinical trial of VX-670 for DM1 – – Cash runway expected through the second quarter of 2026 with $327 million in cash, cash equivalents and marketable securities as of March 31, 2024 – BOSTON, May 07, 2024 (GLOBE NEWSWIRE) --
GuruFocus.comDirector Peter Kim Acquires 9,048 Shares of Entrada Therapeutics Inc (TRDA)
Director Peter Kim of Entrada Therapeutics Inc (NASDAQ:TRDA) has recently increased his stake in the company.
© 2024 Yahoo. All rights reserved.